AstraZeneca Cost of Goods Sold 2010-2024 | AZN
AstraZeneca annual/quarterly cost of goods sold history and growth rate from 2010 to 2024. Cost of goods sold can be defined as the difference between beginning and ending inventories for tangible products resulting in an expense that reflects production and sales costs.
- AstraZeneca cost of goods sold for the quarter ending June 30, 2024 was $2.183B, a 11.38% increase year-over-year.
- AstraZeneca cost of goods sold for the twelve months ending June 30, 2024 was $8.804B, a 9.67% decline year-over-year.
- AstraZeneca annual cost of goods sold for 2023 was $8.268B, a 33.27% decline from 2022.
- AstraZeneca annual cost of goods sold for 2022 was $12.391B, a 0.37% decline from 2021.
- AstraZeneca annual cost of goods sold for 2021 was $12.437B, a 134.7% increase from 2020.
AstraZeneca Annual Cost of Goods Sold
(Millions of US $) |
| 2023 |
$8,268 |
| 2022 |
$12,391 |
| 2021 |
$12,437 |
| 2020 |
$5,299 |
| 2019 |
$4,921 |
| 2018 |
$4,936 |
| 2017 |
$4,318 |
| 2016 |
$4,126 |
| 2015 |
$4,646 |
| 2014 |
$5,842 |
| 2013 |
$5,261 |
| 2012 |
$5,393 |
| 2011 |
$6,026 |
| 2010 |
$6,389 |
| 2009 |
$5,775 |
AstraZeneca Quarterly Cost of Goods Sold
(Millions of US $) |
| 2024-06-30 |
$2,183 |
| 2024-03-31 |
$2,218 |
| 2023-12-31 |
$2,308 |
| 2023-09-30 |
$2,095 |
| 2023-06-30 |
$1,960 |
| 2023-03-31 |
$1,905 |
| 2022-12-31 |
$2,900 |
| 2022-09-30 |
$2,982 |
| 2022-06-30 |
$2,998 |
| 2022-03-31 |
$3,511 |
| 2021-12-31 |
$4,625 |
| 2021-09-30 |
$3,757 |
| 2021-06-30 |
$2,191 |
| 2021-03-31 |
$1,864 |
| 2020-12-31 |
$1,525 |
| 2020-09-30 |
$1,370 |
| 2020-06-30 |
$984 |
| 2020-03-31 |
$1,420 |
| 2019-12-31 |
$1,378 |
| 2019-09-30 |
$1,351 |
| 2019-06-30 |
$1,063 |
| 2019-03-31 |
$1,129 |
| 2018-12-31 |
$1,637 |
| 2018-09-30 |
$1,153 |
| 2018-06-30 |
$1,012 |
| 2018-03-31 |
$1,134 |
| 2017-12-31 |
$1,225 |
| 2017-09-30 |
$1,249 |
| 2017-06-30 |
$950 |
| 2017-03-31 |
$894 |
| 2016-12-31 |
$1,160 |
| 2016-09-30 |
$900 |
| 2016-06-30 |
$1,062 |
| 2016-03-31 |
$1,004 |
| 2015-12-31 |
$1,269 |
| 2015-09-30 |
$1,041 |
| 2015-06-30 |
$1,067 |
| 2015-03-31 |
$1,269 |
| 2014-12-31 |
$1,667 |
| 2014-09-30 |
$1,415 |
| 2014-06-30 |
$1,307 |
| 2014-03-31 |
$1,453 |
| 2013-12-31 |
$1,440 |
| 2013-09-30 |
$1,238 |
| 2013-06-30 |
$1,317 |
| 2013-03-31 |
$1,266 |
| 2012-12-31 |
$1,398 |
| 2012-09-30 |
$1,274 |
| 2012-06-30 |
$1,346 |
| 2012-03-31 |
$1,375 |
| 2011-12-31 |
$1,612 |
| 2011-09-30 |
$1,593 |
| 2011-06-30 |
$1,482 |
| 2011-03-31 |
$1,339 |
| 2010-12-31 |
$1,759 |
| 2010-09-30 |
$1,524 |
| 2010-06-30 |
$1,452 |
| 2010-03-31 |
$1,654 |
| 2009-12-31 |
$1,665 |
| 2009-09-30 |
$1,263 |
| 2009-06-30 |
$1,464 |
| 2009-03-31 |
$1,383 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Large Cap Pharmaceutical |
$243.642B |
$45.811B |
|
AstraZeneca plc, is one of the largest biopharmaceutical companies in the world. AstraZeneca's business can be broken down into separate lines based on therapeutic classes. These include cardiovascular, respiratory, immunology, oncology, rare diseases and other.In July 2021 AstraZeneca closed the acquisition of rare disease drugmaker, Alexion. The acquisition added Alexion's five marketed rare disease products and its pipeline of immune-mediated rare disease candidates.In order to bolster its respiratory portfolio, AstraZeneca acquired rights to Allergan's branded respiratory business in the U.S. and Canada in Mar 2015. The company also acquired Takeda's core respiratory business in May 2016.In June 2007, AstraZeneca acquired biotechnology company MedImmune. In Aug 2011, AstraZeneca sold its Astra Tech business to DENTSPLY. AstraZeneca entered into a number of deals and struck agreements with companies such as FibroGen and Daiichi Sankyo.
|
